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Abstract 
The Hedgehog (HH) signaling pathway has critical roles in embryonic development and 
tumorigenesis. Aberrant activation of HH signaling has been known to be involved in several types of 
malignant tumors. GLI1 is a transcription factor that acts not only as the terminal effector but also 
represents a pathway target gene, amplifying the HH signal. GLI1 expression/activity is modulated at 
different levels of gene regulation. The aim of the thesis is to explore the functional alterations in 
GLI1 transcriptional activity and further investigate the consequences on the output of HH signaling. 
Paper I. We discovered an antisense transcript, which is a long non-coding RNA located head-to-head 
with the gene encoding GLI1, and termed it GLI1 antisense (GLI1AS). The expression of GLI1AS in 
cancer cells was concordant with GLI1 levels. GLI1AS knockdown upregulated GLI1, increased 
cellular proliferation and tumor growth in a xenograft model system. GLI1AS overexpression 
decreased the levels of GLI1, its target genes and cellular proliferation. Additionally, we demonstrated 
that GLI1 knockdown reduced GLI1AS, while GLI1 overexpression increased GLI1AS, highlighting 
a regulatory feedback loop on GLI1/GLI1AS expression. GLI1AS acts by modifying the chromatin 
landscape and reduces the recruitment of RNA polymerase II at the GLI1/GLI1AS locus. 
Paper II. We examined the possible interplay of S6K1 and GLI1 signaling in neuroblastoma. 
mTOR/S6K1 signaling is known to have a role in the development of this disease and recent evidence 
also implicates the HH pathway. In this paper, it is shown that knockdown of either S6K1 or GLI1 
reduces the cellular proliferation of neuroblastoma cells. However, there is little effect of S6K1 on the 
expression of GLI1 mRNA and protein and on the capacity of GLI1 to activate target genes. No 
detectable phosphorylation of GLI1 is observed prior or following S6K1 knockdown. Moreover, no 
additional growth inhibitory effects were detected when PI3K/mTOR and GLI signaling inhibitors 
were combined. Our results demonstrate that the impact of S6K1 kinase on neuroblastoma cells is not 
mediated through modulation of GLI1 expression/activity. 
Paper III. We investigated HH signaling activation in breast cancer and the contribution of GLI1 to 
tamoxifen resistance. Our results showed that GLI1 expression was higher in tamoxifen resistant 
compared to sensitive cells. Tamoxifen resistant cells had stronger ERα transcriptional activity relative 
to sensitive cells, even though the ERα expression was similar in both cell types. Knockdown of GLI1 
attenuated cell proliferation and reduced ERα transcriptional activity in both resistant and sensitive 
cells, irrespective of estrogen stimulation. Moreover, a positive correlation between GLI1 and ERα 
expression was identified in breast cancer samples. High GLI1 expression predicted worse distant 
metastasis-free survival in breast cancer patients. These data suggest that the HH pathway may be a 
new candidate for therapeutic targeting and prognosis in ERα-positive breast cancer. 
Paper IV. We explored the common and differential target genes of GLI1 and edited GLI1, using 
single molecule RNA sequencing (RNA-seq), via overexpression and siRNA-mediated depletion 
approaches in rhabdomyosarcoma Rh36 cells. GO analysis revealed that GLI1 and edited GLI1 are 
involved in developmental and metabolic processes, cellular proliferation, KEGG pathways in cancer, 
basal cell carcinomas and thyroid cancer. 37 genes were differentially upregulated by edited GLI1, 
while 29 common target genes, including FOXS1, SOSTDC1 and SOX18, were identified by RNA-seq 
combined with correlation analysis to the FANTOM5 dataset. SOSTDC1 and FOXS1 expression was 
also modulated in HH signaling responsive medulloblastoma Daoy cells by GLI1 knockdown and 
Smoothened agonist (SAG) treatment. Reciprocally, GLI1 was downregulated in both Rh36 and Daoy 
cells following FOXS1 knockdown, highlighting a FOXS1/GLI1 regulatory loop. 
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1 Introduction 
1.1 Hedgehog signaling pathway 
The Hedgehog (HH) signaling pathway was first described in the context of cell fate 
determination and patterning of Drosophila melanogaster [1]. Mutations in the gene 
encoding the ligand of the pathway resulted in an abnormal spiky-haired phenotype of 
Drosophila, thus the name Hedgehog. Subsequently, it was observed that HH controls cell 
proliferation, cell differentiation, epithelial-mesenchymal transitions, stem cell maintenance 
and patterning of tissues and organs during embryogenesis. The three HH homologs, Sonic 
Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog (DHH), are all involved in 
human developmental processes, with SHH being the most widely studied. The basic HH 
signaling cascade consists of several steps [2] and the key components of the pathway in 
Drosophila are conserved in human [3].  
 
Figure 1. Hedgehog signal transduction. 
(A) In the absence of HH ligand, PTCH inhibits the signaling molecule SMO. (B) Secreted HH binds to its 
receptor PTCH, PTCH inhibition of SMO is relieved and activated SMO releases GLI from cytoplasmic 
sequestration by SUFU. GLI translocates to the nucleus and upregulates the transcription of target genes.  
Primary cilia function as a signaling center for embryonic development and are specialized 
for HH signal transduction [4]. As shown in Figure 1, in the absence of HH, Patched 
(PTCH1 and PTCH2) inhibits the signaling of the seven trans-membrane domain protein, 
proto-oncogene Smoothened (SMO). The negative regulator of the pathway, SUFU 
(Suppressor of Fused), interacts with GLI (Glioma-associated oncogene) in the cytoplasm, 
preventing GLI mediated transcription. Upon HH secretion, the ligand binds to its receptor 
PTCH, HH-bound PTCH activates SMO and the activated SMO releases GLI from 
cytoplasmic sequestration by SUFU [5-8]. In turn, GLI translocates to the nucleus, eliciting 
the transcriptional activation of target genes. The three members of the GLI family are all 
important in mediating HH signaling. GLI2 and GLI3 are thought to have both activator and 
repressor functions, whereas GLI1 only acts as an activator [9, 10]. GLI1 is a terminal 
signaling effector but also represents a pathway target gene [11], amplifying the HH signal. 
Its expression levels thus correlate directly with pathway activity. Interestingly, the 
components of the pathway, PTCH and HHIP (HH interacting protein), are also targets of 
GLI1. 
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1.1.1 Aberrant Hedgehog signaling in human cancer 
Mutations in HH signaling components and aberrant activation of the HH pathway have been 
implicated in developmental abnormalities [12, 13] and tumorigenesis [14-17]. It has been 
reported that numerous types of cancer are associated with abnormal HH pathway activation, 
including basal cell carcinoma (BCC), medulloblastoma, rhabdomyosarcoma, neuroblastoma 
[18], breast cancer, meningioma [19, 20], colon cancer [21, 22], and pancreatic cancer [23].  
Mutation-driven mechanisms, such as loss of function of PTCH1 and gain of function of 
SMO, resulting in constitutive activation of the HH pathway, have been demonstrated in 
BCC [24-26], medulloblastoma [27] and rhabdomyosarcoma [28, 29]. Loss of function 
mutations in SUFU, the negative regulator of the HH pathway, can also promote the 
development of BCC [30]. Germline mutations in SUFU increase the risk to develop Gorlin 
syndrome-associated childhood medulloblastoma [31]. 
High expression of HH pathway components in breast cancer, including GLI1, is associated 
with unfavorable prognosis and progressive stages of the disease [32]. It is also shown that 
the HH pathway has important roles in regulating the development of neural crest stem cells 
and the sympathetic nervous system [33, 34]. One study found that 58-70% of the tumor 
samples among 40 human neuroblastoma specimens expressed significant levels of SHH, 
PTCH1, SMO and GLI2 [35]. Remarkably, this pathway is active in various types of cancer 
stem cells (CSCs), maintaining their properties, including self renewal and epithelial-
mesenchymal transition. Nanog, a stemness gene, is highly expressed in stem cells of the 
cerebellum and of medullobalstomas, and co-expressed with GLI1. Both GLI1 and GLI2 
could regulate the activity of a Nanog reporter construct containing the cis-regulatory 
promoter sequences in mouse and human stem cells [36]. These observations reveal the 
involvement of the HH pathway in the regulation of stemness properties of cancer cells.  
1.1.2 Crosstalk between Hedgehog and other signaling pathways 
The signal transduction of the HH pathway can also be mediated through the involvement of 
additional intracellular signaling cascades [16, 37, 38], including TGF-β (transforming 
growth factor beta), mTOR/S6K1 (mammalian target of rapamycin/ribosomal p70S6 kinase 
1), PI3K (phosphoinositide 3-kinase), MAPK (mitogen-activated protein kinase), HER2 
(human epidermal growth factor receptor 2), WNT, NOTCH and NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells).  
TGF-β-induced GLI2 upregulates GLI1 expression in normal fibroblasts, keratinocytes and 
various cancer cell lines [39]. Consistently, in the skin of a transgenic mouse model 
overexpressing TGF-β1, the expression of Gli1 and Gli2 is increased and depends on Smad3, 
the transcription factor that is activated by TGF-β, with the HH/PTCH/SMO axis not being 
involved. Similarly, Wang et al [40] showed that mTOR/S6K1 activates GLI1 in a SMO-
independent manner. S6K1-mediated phosphorylation of GLI1 increases its transcriptional 
activity and oncogenic function upon TNF-α induction in esophageal adenocarcinoma. 
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Moreover, Ramaswamy et al found a crosstalk between HH and PI3K/AKT pathway in 
breast cancer [41]. They reported that the levels of SMO and GLI1 are significantly elevated 
in tamoxifen-resistant cells. The PI3K/AKT pathway activates HH signaling, bypassing the 
blockade of ERα (estrogen receptor alpha) signaling that was elicited by tamoxifen treatment.  
The importance and the complexity of HH signaling regulation in various types of cancer not 
only implicates the HH pathway as a potential pharmacological target but also provides 
additional possibilities for the development of better therapies based on combinatorial 
inhibitory approaches. Certainly, it will be a challenge to properly select optimal inhibitors 
for therapeutic purpose and avoid severe side effects. 
1.2 Long non-coding RNA 
Advances in sequencing technologies have given researchers the opportunity to more fully 
appreciate the complexity of the transcriptome. Only 2% of the mammalian genome codes 
for proteins, while 75% to 95% of the genome is transcribed, producing a large population of 
non-coding RNAs (ncRNAs) [42], including short ncRNAs (less than 200 nucleotides in 
length) and long ncRNAs (lnRNAs) (over 200 nucleotides in length) [43, 44]. Similar to 
protein-coding mRNAs, lncRNAs are mainly transcribed by RNA polymerase II, are 
5’capped, polyadenylated and spliced, but have very low coding potential [45]. The 
promoters of lncRNAs are also marked by active histone modifications, such as H3K4me, 
H3K4me3, H3K9ac and H3K27ac, but also slightly enriched in markers associated with both 
repression (H3K27me3) and activation (H3K36me3), compared to those of protein-coding 
genes [46]. Although most lncRNAs evolve rapidly as far as their sequences and expression 
levels are concerned, their promoter sequences and their tissue specificities are conserved, 
similarly to protein-coding genes [47]. A comparison of the characteristics of lncRNA and 
coding mRNA is shown in Table 1. 
                                                Table 1. Comparison of lncRNA and mRNA 
Characteristics lncRNA mRNA 
5’ capped ✔ ✔ 
3’ polyadenylated ✔ ✔ 
RNA poly II transcription  ✔ ✔ 
Spliced ✔ ✔ 
Protein coding  ✔ 
No obvious ORF ✔  
Low expression level ✔  
Low sequence conservation ✔  
Fast evolution ✔  
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1.2.1 The regulatory mechanisms and biological functions of lncRNA 
LncRNAs exert their functions through different mechanisms. LncRNAs can recruit 
chromatin-modifying complexes and change the landscape of specific DNA loci. LncRNAs 
can bind and inhibit RNA polymerase II directly, in addition to inhibiting the nuclear 
translocation of certain transcription factors by binding the specific transporters. LncRNAs 
undergo conformational changes and fold into specific structures, mimicking DNA-binding 
sites, and inhibit/enhance the activity of specific transcription factors. LnRNAs can act as 
scaffolds and recruit proteins into a complex, which is targeted to a specific locus, leading to 
transcriptional repression or activation. To date, a large number of studies have revealed that 
lncRNAs regulate embryogenesis, neurogenesis [48], mRNA splicing [49], gene expression 
[50], control of gene transcription [51], translation [52], gene imprinting [53], disease 
progression, especially in cancer, including glioma and BCC [54].  
1.2.2 Natural antisense transcripts 
Global transcriptome analysis has shown that up to 70% of sense transcripts have antisense 
partners, which are transcribed from the opposite DNA strand, and primarily these are 
lncRNAs [55]. Antisense transcripts regulate gene expression of the corresponding sense 
transcripts either in a concordant or discordant way [56, 57]. Knockdown of the antisense 
may result in the decrease of the sense transcript, which indicates concordant regulation, 
whereas knockdown of the antisense that increases the sense transcript indicates discordant 
regulation.  
Two classic examples of natural sense/antisense transcript regulation are involved in 
developmental processes and cancerous growth [55]. (1) Xist is a lncRNA, transcribed from 
the X inactivation centre in the inactive X chromosome, while Tsix is transcribed from the 
opposite strand, overlapping the Xist locus [58]. Lee et al reported that both X chromosomes 
express Tsix before X inactivation starts; at the onset of X inactivation, Tsix expression 
becomes monoallelic and persists until Xist expression is turned off. They concluded that Tsix 
regulates X inactivation at the early steps, but not at the later, chromosomal silencing steps. (2) 
Wrap53, a natural antisense transcript of p53, regulates p53 in a concordant manner [59]. 
Knockdown of Wrap53 reduces the expression of p53; conversely, Wrap53 overexpression 
increases the mRNA and protein levels of p53. The underlying mechanism is that a Wrap53-
p53 RNA duplex maintains the stability of the p53 mRNA. Interestingly, Wrap53 can also 
regulate mutant p53. This makes Wrap53 a good therapeutic target for the treatment of 
cancers with p53 mutations. 
The regulatory mechanisms of antisense transcripts can be divided into four types, epigenetic 
regulation, RNA-DNA interaction, RNA-RNA interaction in the nucleus and RNA-RNA 
interaction in the cytoplasm [60]. Of these, the antisense RNA-mediated epigenetic 
modifications have been supported by a large amount of experimental studies. Antisense 
transcripts can serve as scaffolds for proteins and interact with DNA/chromatin at specific 
loci, e.g., cis-acting epigenetic silencers, Kcnq1ot1 [61] and ANRIL [62]; cis-acting 
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epigenetic activators, Evx1as and Hoxb5/6as [63]; trans-acting chromatin remodelers, 
HOTAIR [64] and HOTTIP [65]. 
It would be interesting to explore possible antisense transcript(s) against the key components 
of HH signaling, investigate their regulatory role on the expression of the corresponding 
sense transcript and their effects in modulating the HH pathway activity. (Paper I) 
1.3 The role of GLI1 modifications in Hedgehog signaling  
It has been reported that GLI1 expression and function can be regulated at different levels, 
including post-transcriptional and post-translational. Such modulations on GLI1 result in 
differential functions relative to the wild type GLI1, and influence the activity of the HH 
pathway. 
1.3.1 Edited GLI1  
RNA editing is an RNA processing mechanism that includes nucleotide insertion, deletion 
and modification, but excludes RNA splicing, polyadenylation and degradation [66]. In 
mammals, the most common type of RNA editing is nucleotide substitution, with A 
(adenosine) to I (inosine) editing being a prevalent type of RNA editing, which is mediated 
by the ADAR (adenosine deaminase acting on RNA) enzymes. Since inosine is recognized as 
a guanosine by most enzymes, A to I editing of protein-coding mRNAs can result in codon 
changes, which may subsequently induce alterations in protein function [67].  
Remarkably, Shimokawa et al reported that the GLI1 mRNA is A to I edited at nucleotide 
2179. This A to I substitution causes a codon change from Arginine to Glycine at position 
701. GLI1 editing is prevalent in normal human cerebellum, but in medulloblastoma cell 
lines the extent of this event is severely reduced [68]. Consistently, BCC tumor samples show 
decreased GLI1 editing in comparison with normal skin. Compared to GLI1, edited-GLI1 
exhibits a slightly higher capacity in transcriptional activation and is less sensitive to 
inhibition by SUFU. However, it is less effective in promoting cell growth. Additional studies 
revealed novel isoforms of GLI1 generated by alternative splicing [69], including GLI1ΔN 
(N-terminal deletion variant) [70] and tGLI1 (truncated GLI1) [71], which increase the 
functional diversity of the GLI1 protein. The structures of the GLI1 mRNA isoforms are 
shown in Figure 2. 
 
full length GLI1
edited GLI1
tGLI1
GLI1ΔN
E1             E2   E3          E4    E5 E11 E12
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Figure 2. The structures of the different GLI1 mRNA isoforms.  
Full length GLI1 mRNA contains 12 exons spanning 3618 nucleotides. Compared to full length GLI1, edited 
GLI1 has guanosine (inosine), not adenosine, at nucleotide 2179, generated by adenosine deamination, leading to 
a change from Arginine to Glycine at position 701 in the GLI1 protein, yellow indicates the edited nucleotide; 
GLI1ΔN mRNA lacks two coding exons, exon 2 and exon 3, resulting in translation initiation from an internal 
AUG site and a N-terminally truncated protein isoform; tGLI1 lacks exon 3 and part of exon 4, resulting in a 
shorter protein isoform, red indicates the truncated exon. Exons (E) are numbered and shown by black rectangles. 
Translation initiation sites are indicated by arrowheads. 
Thus, it is worthwhile to explore the differential target genes of GLI1 and edited GLI1 with 
the help of high throughput RNA sequencing techniques, and to further dissect the 
consequences and mechanisms underlying HH signaling activation. (Paper IV) 
1.3.2 Phosphorylated GLI1 
Functional diversity in GLI1 can result not only post-transcriptionally, but also from post-
translational modifications, including ubiquitination [72], acetylation [73], SUMOylation [74] 
and phosphorylation [40, 75, 76], with GLI1 phosphorylation being mostly analysed, as 
shown in Figure 3 [77, 78]. 
 
Figure 3.  GLI1 protein structure and the phosphorylation sites.  
GLI1 contains a SUFU binding domain (black) and five zinc finger domains that bind to DNA (purple). GLI1 
phosphorylation sites are shown [78]. Phosphorylation at Serine 243 (S243) and Threonine 304 (T304) has been 
implicated in increased GLI1 transcriptional activity, while phosphorylation at S102, T374, S408 and T1074 has 
been linked to decreased GLI1 transcriptional activity. Y, Tyrosine. 
Shi et al reported that the member of the Src kinase family, Hck, interacts with GLI1 and 
phosphorylates GLI1 at multiple tyrosine sites, leading to enhanced transcriptional activity of 
GLI1 [76]. Additionally, Li et al reported that phosphorylation of GLI1 at Serine 102, Serine 
408 and Threonine 1074 by AMPK (AMP-activated protein kinase) reduces GLI1 protein 
stability [79]. Prevention of AMPK-mediated phosphorylation improved the protein stability 
and maintained the transcriptional activity of GLI1. 
Notably, Wang et al reported that S6K1 phosphorylates GLI1 at Serine 84 independent of 
SMO, and this increases its transcriptional activity and its oncogenic function in esophageal 
adenocarcinoma (EAC). The combination of inhibitors to the mTOR/S6K1 and HH pathways 
had a more potent inhibitory effect on EAC cells than the use of a single agent alone. Taken 
together, the data suggest that a crosstalk between the mTOR/S6K1 and HH pathways 
provides a mechanism for SMO-independent GLI1 activation.  
Interestingly, both the mTOR and HH pathways are abnormally activated in neuroblastoma, 
as inhibitors targeting either the mTOR [80] or the HH pathway [81] could block cell growth 
S84 S102 S132 S243 T304 T374 S408 S544 S560 Y800 T1074S1071S640
 SUFU binding domain  Zinc fingers (DNA binding domain)
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in vitro and in vivo. Consequently, it was justified to examine the GLI1 phosphorylation 
status elicited by S6K1 and the possible interplay between these two pathways in 
neuroblastoma. (Paper II) 
1.4 Hedgehog pathway and tamoxifen resistance  
Based on the expression of molecular biomarkers, ERα, PR (progesterone receptor), and 
HER2, breast cancer is classified into 6 subtypes, basal-like, HER2-enriched, normal breast-
like, luminal A, luminal B and claudin-low, with different subtypes leading to different 
prognosis [82]. ERα signaling has a critical role in the development and growth of hormone-
dependent breast cancer. The domain structure and ligand dependent gene regulation of ERα 
are shown in Figure 4.  
 
 
 
 
Tamoxifen is the most commonly used ER modulator for 
the treatment of ERα positive breast cancer, which accounts for 70% of all human breast 
cancer cases, including luminal A and luminal B. However in 20-30% of the patients 
receiving tamoxifen the tumor relapses [83]. This is a major challenge for breast cancer 
treatment.  
1.4.1 The mechanisms of tamoxifen resistance 
The mechanisms of intrinsic and acquired resistance to tamoxifen have been extensively 
investigated [84-87], and may include genetic changes, epigenetic and post-translational 
modifications. The point mutations in ERα E380Q, Y537S and D538G reduce the inhibitory 
efficacy of tamoxifen [88]. In particular, the Y537S and D538G mutations occur at the N-
terminus of Helix 12 in the ligand binding domain (LBD) of ERα, promoting the binding of 
LBDHingeDBD
AF-1 domain AF-2 domainA
Estrogens
ER ER ER ER ER
ER ER
ERE
P P P
P P Transcription
B
Figure 4. The domain structure of 
ERα and the classical model of ER 
mediated gene transcription. 
(A) ERα contains a number of 
functional domains, AF-1 domain 
(activation function 1 domain), DBD 
(DNA-binding domain), Hinge, LBD 
(ligand binding domain) and AF-2 
domain (activation function 2 
domain).  The activation of AF-1 
domain is ligand-independent, while 
the activation of AF-2 domain is 
ligand-dependent. (B) Estrogen 
binding to the estrogen receptor leads 
to its dissociation from chaperones, 
conformational alterations, 
phosphorylation and dimerization. 
The ligand-bound ER complex binds 
to ERE (estrogen response element) 
in the promoter region and activates 
the transcription of estrogen-
dependent genes via the recruitment 
of co-regulatory factors. 
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constitutive co-activators to ERα and reducing the binding affinity to estradiol and tamoxifen 
[89]. Additionally, ERα expression may be lost in some patients who develop acquired 
tamoxifen resistance [90, 91]. Stone et al observed that hypermethylation at ERα enhancer 
regions is associated with a reduction in the DNA binding of ERα in tamoxifen resistant cells, 
and this downregulates the expression of key modulators of ERα activity. Notably, the 
methylation status of ERα enhancers determines the outcome of tamoxifen treatment [92]. 
Additionally, ERα phosphorylation is also relevant for the tamoxifen response [93]. For 
instance, phosphorylation at Serines 102/104/106 [94] and 305 [95] has been linked to 
tamoxifen resistance.  
Moreover, mutations in ERα co-regulators [83, 84], the involvement of non-coding RNAs 
[96] and cellular kinase signaling pathways, e.g., receptor tyrosine kinases and MAPK 
pathways [83, 87] are also implicated in tamoxifen resistance.  
1.4.2 Hedgehog signaling and breast cancer development 
Links between HH signaling activation and breast cancer development have been suggested 
in a number of studies [97-99]. Hypomethylation of the SHH promoter results in an elevated 
expression of this HH ligand. High expression of SHH and GLI1 indicate high risk of 
metastasis and poor prognosis in a cohort of 279 patients with invasive ductal breast cancer 
[100]. Conditional expression of GLI1 in the mouse mammary gland induces the proliferation 
of epithelial cells and tumor formation [101]. Sun et al showed that estrogen promotes the 
CSC development and epithelial-mesenchymal transition in ERα-positive breast cancer cells 
by increasing GLI1 expression [102]. Furthermore, estrogen stimulation increases GLI1 
nuclear translocation and regulates the progression from non-invasive to invasive breast 
cancer [103]. Constitutive activation of HH signaling in MMTV-SmoM2 transgenic mice 
caused alterations in mammary gland morphology, increased proliferation, and changed 
stem/progenitor cell numbers [104]. Taken together, these studies provide insights into the 
mechanisms of HH signaling activation in the mammary gland and its possible role in breast 
tumorigenesis. 
Interestingly, in 2012 Ramaswamy et al first reported that HH signaling mediates tamoxifen 
resistance in breast cancer cells [41]. Compared to tamoxifen sensitive cells, tamoxifen 
resistant cells express higher levels of GLI1 and SMO, and have stronger GLI1 
transcriptional activity. In in vivo assays, the SMO inhibitor GDC-0449 alone or in 
combination with tamoxifen suppresses the tumor growth of tamoxifen resistant cells. The 
proposed mechanism implicates a highly activated PI3K/AKT pathway, which blocks the 
degradation of GLI1 and SMO in tamoxifen resistant cells. This study suggests that the HH 
pathway is a potential target for the treatment of tamoxifen resistant breast cancer. This work 
also sparked our interest to further investigate the role of HH signaling in breast cancer and 
the underlying molecular mechanisms. (Paper III) 
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2 Aims of the thesis  
Aberrant activation of HH signaling has been implicated in many malignancies and includes 
canonical activation by HH ligands/mutations in components of the pathway or non-
canonical activation, which occurs independent of HH/PTCH/SMO via other signaling 
cascades. The effector of the pathway, the transcription factor GLI1, can undergo diverse 
modifications at the epigenetic, post-transcriptional and post-translational levels. 
Consequently, the general aim of the thesis was to investigate the consequences of this GLI1 
modulation on the HH signaling activity. 
2.1 Dissect the possible regulation of GLI1 by a non-coding GLI1 antisense transcript and 
uncover the regulatory mechanisms underlying the interplay between GLI1 and GLI1AS.  
2.2 Investigate the crosstalk between the mTOR/S6K1 and HH pathways in neuroblastoma 
cells, examine the GLI1 phosphorylation status and possibly, provide novel therapeutic 
strategies by targeting both pathways. 
2.3 Determine the impact of GLI1 on ERα signaling, and characterize the role of GLI1 in 
breast cancer and tamoxifen resistance. 
2.4 Explore the differential target genes of GLI1 and edited GLI1 by RNA sequencing, and 
their impact on biological processes mediated by this transcription factor. 
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3 Results and conclusions  
3.1 Paper I 
Identification of novel non-coding RNA-based negative feedback regulating the 
expression of the oncogenic transcription factor GLI1 
In silico analysis of EST databases and RACE analysis in rhabdomyosarcoma Rh36, CCA 
and RMS13 cells revealed that the GLI1AS RNA initiates 155 nucleotides upstream of the 
major transcription start site of the GLI1 gene in an opposite orientation, consists of 885 
nucleotides and three exons, is 5’ capped and 3’ polyadenylated but without any long open 
reading frame (GenBank accession number JX675466).  
Expression analysis of GLI1AS showed a remarkable co-regulation with GLI1 in cancer 
cell lines, basal cell carcinoma and breast tumor samples. GLI1AS transcripts retaining 
intron 1 or intron 2 were more abundant than transcripts with the introns being removed. 
The unspliced GLI1AS RNA is preferentially localized in the nucleus, while the spliced 
GLI1AS RNA transported to the cytoplasm.  
SiRNA-mediated GLI1AS depletion in Rh36 cells resulted in an increase of GLI1 
expression. On the contrary, GLI1 knockdown decreased GLI1AS levels in both Rh36 and 
CCA cells. Consistently, EdU incorporation assays showed a decrease in cellular 
proliferation by GLI1 depletion and an increase by GLI1AS knockdown. The chick 
chorioallantoic membrane xenograft model demonstrated that treatment of Rh36 cells with 
GLI1 siRNAs decreased their capacity to form tumors, while an increased tumor weight 
was observed following treatment with GLI1AS siRNAs.  
Expression of the full-length GLI1AS construct but not the 5’ or the 3’ segment of GLI1AS 
resulted in a reduction in GLI1 mRNA and protein, and a decrease in PTCH1 and PTCH2 
expression. These findings suggest that the complete GLI1AS RNA sequence/structure is 
needed to elicit regulatory effects on GLI1. Interestingly, the expression of ADAR2, an 
unrelated gene on chromosome 21q22.3, was not changed by GLI1AS overexpression, 
however, the expression of INHBE, a gene positioned tail-to-tail to GLI1AS, was reduced, 
albeit not to the same extent as seen for GLI1. Conversely, GLI1 expression in Rh36 cells 
resulted in an upregulation of GLI1AS, but not INHBE. This suggests that the observed 
INHBE downregulation by GLI1AS overexpression is not an indirect result of the reduced 
GLI1 levels, but rather an effect of the antisense RNA on the organization of the chromatin 
locus.  
Chromatin immunoprecipitation (ChIP) assays revealed that transcriptional repressive 
histone markers were increased throughout the INHBE/GLI1AS/GLI1 genomic regions 
following GLI1AS overexpression. The recruitment of RNA polymerase II showed a 
statistically significant decrease. Thus, GLI1AS appears to act as an epigenetic modifier 
that represses gene expression at its locus. Furthermore, a concordant upregulation of GLI1 
and GLI1AS was elicited by activation of HH or TGF-β signaling.  
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3.2 Paper II 
The impact of S6K1 kinase on neuroblastoma cell proliferation is independent of GLI1 
signaling 
SiRNA-mediated S6K1 depletion in SK-N-AS neuroblastoma cells reduced cellular 
proliferation; GLI1 siRNAs treatment also decreased the proliferation but not to the same 
extent as the S6K1 knockdown, indicating that S6K1 silencing has stronger effects on SK-
N-AS cells than GLI1 silencing. The depletion of GLI1, but not S6K1, decreased the 
expression of SMO, GLI2, GLI3, and PTCH2. Importantly, GLI1 expression was 
unaffected by knocking down S6K1. Thus, the mechanism of S6K1 on SK-N-AS cell 
proliferation is not related to the expression of the HH signaling components analyzed. 
Western blot and immunoprecipitation analysis indicated that GLI1 expression is not 
altered by S6K1 knockdown. Moreover, no GLI1 phosphorylation was observed, 
irrespective of the status of S6K1. Thus, S6K1-dependent phosphorylation of GLI1 is not 
taking place at detectable levels in SK-N-AS cells.  
Ectopic expression of S6K1, the constitutively active mutant S6K1T389E or the function-
loss mutant S6K1T389A in SK-N-AS cells could not confer changes in cellular 
proliferation, neither did GLI1 overexpression. This is in contrast to the observations in 
esophageal adenocarcinoma cells [40]. Importantly, GLI1 overexpression could not rescue 
the reduction of cell proliferation elicited by knocking down S6K1. The data suggest that 
the proliferative effects of endogenous S6K1 and GLI1 have reached saturation in SK-N-
AS cells. 
The cytotoxicity of the GLI inhibitor GANT61 and the PI3K/mTOR inhibitors AR-12 
(OSU03012), CCI-779 and NVP-BEZ235 was evaluated using a fluorometric microculture 
cytotoxicity assay not only in SK-N-AS but also in SK-N-BE(2) cells. No differences 
between the log IC50 of GANT61 and the log IC50 of GANT61 combined with the 
PI3K/mTOR inhibitors (t-test, p > 0.05), except for the combination of GANT61 and CCI-
779 in SK-N-BE(2) cells (t-test, p = 0.032), were observed.  
Thus, we conclude that the impact of S6K1 on the proliferation of the neuroblastoma SK-
N-AS cells is not mediated through GLI1 signaling. 
3.3 Paper III 
Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in 
breast cancer cells 
Expression analysis of key markers of the activity of the HH signaling pathway, i.e., GLI1 
and PTCH1, revealed higher expression in the tamoxifen resistant LCC2 breast cancer cells 
compared to the parental, tamoxifen sensitive MCF7 cells. Notably, the ERα target genes 
ADORA1 and pS2 were upregulated in the resistant cells. Cell viability assays indicated that 
LCC2 but not MCF7 cells are resistant to 10 µM tamoxifen, however 20 µM tamoxifen 
kills both cell types. This analysis demonstrates the higher HH signaling activity in the 
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resistant cells and suggests that ERα activity may also be higher, despite the comparable 
ERα expression [105].  
Depletion of ERα resulted in a major reduction of the cell proliferation in both cell lines, 
highlighting their dependence on ERα. Depletion of GLI1 also reduced the cell 
proliferation of the two cell lines, but to a lesser extent. These observations are in-line with 
the significance of ERα in breast cancer cells [106] and indicate that GLI1 can modulate 
proliferation not only in tamoxifen resistant but also in tamoxifen sensitive cells.  
Estrogen response element (ERE) luciferase reporter assays showed that GLI1 depletion 
reduces ERα activity both in MCF7 and LCC2 cells, irrespective of the presence of 
estrogen. Importantly, the basal level of the ERα transcriptional activity was higher in 
LCC2 compared to MCF7 cells, an observation in-line with the expression pattern of the 
ERα target genes ADORA1 and pS2. These findings suggest an interplay of GLI1 and ERα 
signaling in both tamoxifen resistant and sensitive cells.  
GLI1 depletion decreased the expression of PTCH1, ERα and its target genes, IL20, 
ADORA1 and pS2, in the context of estrogen treatment, while limited effects were observed 
without addition of estrogen. The results were confirmed using two additional ERα-positive 
breast cancer cell lines, ZR751 and T47D. Western blot analysis demonstrated that GLI1 
depletion downregulated ERα in both MCF7 and LCC2 cells. Consistently, ChIP analysis 
revealed decreased ERα binding at the promoter region of its target gene pS2 following 
GLI1 depletion in the presence of estrogen.  
GANT61 treatment resulted in a dose-dependent reduction of the viability of MCF7 and 
LCC2 cells. GANT61 co-administration with tamoxifen further decreased the cell growth 
inhibition elicited by tamoxifen. GLI1 depletion also enhanced the impact of tamoxifen in 
reducing the proliferation of the two cell lines. Similar enhancement of the tamoxifen 
impact by GLI1 depletion was observed in ZR751 and T47D cells. Thus, the role of GLI1 
for the proliferation of ERα-positive breast cancer cells may be exploited for therapeutic 
purposes, and drug targeting of GLI1 could enhance the tamoxifen efficacy in the treatment 
of breast cancer.  
Gene expression analysis revealed that the expression of GLI1 positively correlates with 
ERα gene (ESR1) and the ERα targets genes pS2 and GREB1 using a dataset of breast 
cancer samples from 286 individuals [107]. High GLI1 expression was also found to be 
associated with poor distant metastasis-free survival (DMFS) in 126 patients with Grade 1, 
ERα-positive breast cancer in the Kaplan-Meier Plotter dataset [108]. These findings 
suggest that GLI1 may represent not only a therapeutic target, but could also be a valuable 
prognostic marker for breast cancer patients.  
3.4 Paper IV 
Global analysis of GLI1 and RNA-edited GLI1 target genes  
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RNA from rhabdomyosarcoma Rh36 cells transfected with GLI1, edited GLI1 [68] or GLI1 
siRNAs were used for single molecule RNA sequencing (RNA-seq) via the Helicos 
platform. Upregulated genes with a Z score over 2 were initially selected in the GLI1 or 
edited GLI1 overexpression; downregulated genes with a fold difference over 1.2 were also 
selected in the GLI1 depletion. Combining the overexpression/depletion datasets allowed 
the identification 477 GLI1 and 480 edited GLI1 target genes, 197 of which were common. 
These common target genes were used for GO analysis and curated gene-set enrichment 
analysis.  
Moreover, in a parallel approach the 1000 genes with the highest Z score in the GLI1 and 
edited GLI1 overexpression datasets were subjected to a Spearman correlation with the 
gene expression FANTOM5 datasets of 833 tissues. In both cases a correlation higher than 
by chance was revealed. Combining the GLI1 and edited GLI1 datasets increased the 
Spearman correlation. Inclusion of the criterion of downregulation following GLI1 
depletion further increased the correlation, resulting in a list of 29 genes. Furthermore, 
increasing the stringency to a two-fold downregulation following GLI1 depletion reduced 
the list to 8 genes (one of which being the known GLI1 target PTCH1). Interestingly, 25 
out of the 29 selected genes were present in the previous list of the 197 common targets. In 
addition, heat maps generated for the 29 selected genes, using both the GLI1 
overexpression and knockdown datasets, showed clear up- and downregulation respectively, 
compared with 29 randomly selected genes. Finally, a Spearman correlation distribution 
analysis demonstrated a higher correlation with GLI1 expression of the 29 selected genes in 
comparison to the 29 random genes.  
Among the 29 selected target genes, 14 genes were validated by RT-qPCR in Rh36 cells 
following GLI1 depletion. Moreover, two genes, FOXS1 and SOSTDC1, were also 
validated in GLI1 and edited GLI1 overexpressions in Rh36 cells and in medulloblastoma 
Daoy cells following Smoothened agonist (SAG) treatment. Notably, the induction of 
SOSTDC1 and FOXS1 by SAG was suppressed in CRISPR/Cas9-mediated GLI1 knockout 
Daoy subclones. Surprisingly, FOXS1 knockdown resulted in the reduction of GLI1 
expression, indicating a FOXS1-GLI1 regulatory loop.  
To identify target genes that are differentially upregulated by GLI1 and edited GLI1, the top 
1000 genes with the highest Z score in the GLI1 or edited GLI1 overexpressions were filtered 
for absence in the reciprocal overexpression and for downregulation in GLI1 depletion, 
followed by a Spearman correlation with the gene expression FANTOM5 datasets. The 
correlation of the selected list for GLI1 overexpression was in the random range, while a list 
of 37 genes with a statistically significant correlation was generated for the edited GLI1 
overexpression, three of which were also validated by RT-qPCR in biological replicates. 
Interestingly, expression of the typical GLI1 target gene HHIP, but not PTCH1, was also 
found to be preferentially upregulated by the edited compared to the non-edited GLI1 in 
Rh36 cells. 
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4 Future perspectives 
Hedgehog-GLI1 signaling is widely studied using a variety of different methodological 
approaches, but no reliable Western blot/ChIP graded antibodies against GLI1 are available, 
possibly due to the complex GLI1 structure, and this narrows the effectiveness of GLI1 
functional studies. To further expand on some of the projects in this thesis, we will first aim 
to add an epitope tag on the C-terminus of endogenous GLI1 using the CRISPR/Cas9 
technology. Secondly, we will employ the adeno-associated virus (AAV) expression system 
for tagged GLI1/edited GLI1 overexpression [109], in order to overcome both the lack of 
effective antibodies and the low efficiency of transient plasmid transfection. 
In Paper III, we showed that GLI1 depletion downregulated ERα expression, reduced ERα 
transcriptional activity and its recruitment on the pS2 promoter, suggesting that GLI1 has a 
role in modulating the transcription of ERα/ERα target genes. By modulating GLI1 
expression levels through CRISPR/Cas9 and/or AAV systems, we may detect GLI1-ERα 
interactions by immunoprecipitation and clarify the involvement of GLI1 in ERα regulated 
gene expression using GLI1 ChIP-qPCR or ChIP-seq. To investigate the possibility of GLI1 
acting as a co-regulator in ER transcriptional activation, we could do ChIP and re-ChIP using 
antibodies against ERα and the epitope tag, respectively.  
In Paper IV, we performed CRISPR/Cas9 mediated GLI1 knockout in Daoy cells and 
obtained three Daoy subclones with compromised GLI1 activity and HHIP expression upon 
SAG treatment. Next, we will verify the genomic changes in the GLI1 gene by genomic PCR 
and reverse transcription PCR. We will continue to validate the differential targets of GLI1 
and edited GLI1 by RT-qPCR. To confirm the GLI1 target potential of FOXS1 and 
SOSTDC1, we will engage into luciferase reporter assays, using promoter constructs of these 
two genes combined with GLI1 overexpression. We will proceed with GLI1/edited GLI1 
ChIP-qPCR to validate the identified target genes, including FOXS1 and SOSTDC1, as direct 
targets in Rh36 cells using the AAV expression system. To further examine the role of 
FOXS1, we will determine the impact of siRNA-mediated FOXS1 depletion in Daoy cell 
proliferation with or without SAG treatment, followed by expression analysis of key 
components in HH signaling. 
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